Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | CLK1 | P49759 | 13/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | CLK2 | P49760 | 3/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4580171 | 0.85 | BACE1 (0.67) | BACE1CA2PDE3BPDE3ACLK1 | |
| SCHEMBL144533 | 0.76 | BACE1 (0.65) | BACE1CA2PDE3BPDE3ACLK1 | |
| SCHEMBL1403727 | 0.74 | CYP1A2 (0.60) | CA2CYP1A2CYP2A6CYP3A4 | |
| SCHEMBL2175746 | 0.74 | BACE1 (1.00) | BACE1CA2PDE3BPDE3ACLK1 | |
| SCHEMBL5546367 | 0.74 | BACE1 (0.62) | BACE1CA2PDE3BPDE3ACLK1 | |
| SCHEMBL16023592 | 0.74 | BACE1 (0.62) | BACE1CA2PDE3BPDE3ACLK1 | |
| SCHEMBL760770 | 0.74 | EGFR (0.37) | CLK1DYRK1ADYRK1BCYP3A4 | |
| SCHEMBL1763599 | 0.71 | AGXT (0.44) | CA2CYP2A6 | |
| SCHEMBL12778904 | 0.70 | BACE1 (0.57) | BACE1CA2PDE3BPDE3ACLK1 | |
| SCHEMBL6839989 | 0.70 | BACE1 (0.62) | BACE1CA2PDE3BPDE3ACLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | BACE1 687/4885CA2 3954/4885PDE3B 295/4885 |
| US-20120053345-A1 | Indazole Compounds | CYP3A43, CYP3A7, UGT1A1 | BACE1 687/4885CA2 3954/4885PDE3B 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.